Advertisement
LabX
LabX

Triple therapy safety

NEW YORK, July 18 (Praxis Press) Multidrug antiretroviral therapy has decreased the morbidity and mortality associated with human immunodeficiency virus (HIV) infection, but the long-term effects and safety of this treatment are unknown. Gulick and colleagues studied the durability and toxicity associated with combined indinavir, zidovudine and lamivudine therapy in HIV-infected patients (see paper). Almost 65% of patients continued therapy for three years. Serum viral loads remained suppressed

July 21, 2000

NEW YORK, July 18 (Praxis Press) Multidrug antiretroviral therapy has decreased the morbidity and mortality associated with human immunodeficiency virus (HIV) infection, but the long-term effects and safety of this treatment are unknown. Gulick and colleagues studied the durability and toxicity associated with combined indinavir, zidovudine and lamivudine therapy in HIV-infected patients (see paper). Almost 65% of patients continued therapy for three years. Serum viral loads remained suppressed and CD4 counts remained elevated relative to baseline values. The main adverse effect was nephrolithiasis. Multidrug antiretroviral therapy can achieve prolonged suppression of HIV viremia.

Advertisement
Lonza Group
Lonza Group

Popular Now

  1. LabQuiz: What's Your Cell IQ?
    Sponsored Quiz LabQuiz: What's Your Cell IQ?

    Your body is made up of trillions of cells—but what do you really know about them? Take our lab quiz and determine your CIQ (cell identification quotient). 

  2. Immune Defect Detected in Knockout Mice
  3. Antibiotics From Scratch
  4. Antibody Maker Loses License Over Animal Welfare Violations
Advertisement
LabX
LabX
Advertisement
LabX
LabX
Biosearch Technologies
illumina Corporate
illumina Corporate